Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Chief Medical Officer | September 04, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date September 04, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,854 |
Reported balance
After 2026-09-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-04 · Sale · Disposed 3,745 · Balance 163,854 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.27 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 162,564 |
Reported balance
After 2026-09-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-08 · Sale · Disposed 1,290 · Balance 162,564 F3: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F5: Includes 125,126 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.27 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F3: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F5: Includes 125,126 unvested RSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Generation Bio Co.
Report date January 29, 2024 · Filed January 31, 2024
Section 16 reporting ended · disclosed 2024-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 385,628 |
Ending reported balance
After 2024-01-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-29 · Exercise / conversion · Acquired 5,021 · Balance 387,104 F1: Each restricted stock unit represents the right to receive one share of the company's common stock. Row 2 · 2024-01-29 · Tax withholding · Disposed 1,476 · Balance 385,628 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-01-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-29 · Exercise / conversion · Disposed 5,021 · Balance 0 F1: Each restricted stock unit represents the right to receive one share of the company's common stock. F2: On January 20, 2023, the reporting person was granted 26,775 restricted stock units. The shares underlying the restricted stock units vest over four years, with 25% of the shares vested on January 15, 2024 and the remaining shares vesting in equal quarterly installments thereafter. F3: Reflects the forfeit of 15,060 restricted stock units in connection with the reporting person's separation from the company. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of the company's common stock.
F2: On January 20, 2023, the reporting person was granted 26,775 restricted stock units. The shares underlying the restricted stock units vest over four years, with 25% of the shares vested on January 15, 2024 and the remaining shares vesting in equal quarterly installments thereafter.
F3: Reflects the forfeit of 15,060 restricted stock units in connection with the reporting person's separation from the company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2021 Filed Jul 12, 2021 20:02 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 1,889 | $25.39 | $47,961.71 |
DisclosureSEC source: 0001415889-21-003583 · form4-07122021_010711.xml · nonDerivative · entry 3 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,558 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.21 to $25.61, inclusive. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:02 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 1,629 | $24.99 | $40,708.71 |
DisclosureSEC source: 0001415889-21-003583 · form4-07122021_010711.xml · nonDerivative · entry 2 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,447 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.20 to $25.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:02 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionCommon Stock | 3,518 | $5.16 | $18,152.88 |
DisclosureSEC source: 0001415889-21-003583 · form4-07122021_010711.xml · nonDerivative · entry 1 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:05 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionStock Option (right to buy) · Derivative | 14,072 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001415889-21-001930 · form4-04072021_010433.xml · derivative · entry 4 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,217 Underlying: Common Stock · 14,072 shares Expires 2030-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F4 · derivative.exercise_date: The option to purchase 56,289 shares of common stock was granted on March 5, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on March 5, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 3,321 | $30.68 | $101,888.28 |
DisclosureSEC source: 0001415889-21-001930 · form4-04072021_010433.xml · nonDerivative · entry 3 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,558 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.36 to $31.17, inclusive. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 10,751 | $29.91 | $321,562.41 |
DisclosureSEC source: 0001415889-21-001930 · form4-04072021_010433.xml · nonDerivative · entry 2 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,879 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.34 to $30.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:05 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionCommon Stock | 14,072 | $5.16 | $72,611.52 |
DisclosureSEC source: 0001415889-21-001930 · form4-04072021_010433.xml · nonDerivative · entry 1 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionStock Option (right to buy) · Derivative | 11,267 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001415889-21-001382 · form4-03092021_010305.xml · derivative · entry 9 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,959 Underlying: Common Stock · 11,267 shares Expires 2028-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F8 · derivative.exercise_date: The option to purchase 123,760 shares of common stock was granted on April 2, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on April 2, 2019 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 100 | $35.58 | $3,558.00 |
DisclosureSEC source: 0001415889-21-001382 · form4-03092021_010305.xml · nonDerivative · entry 8 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,558 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 500 | $34.77 | $17,385.00 |
DisclosureSEC source: 0001415889-21-001382 · form4-03092021_010305.xml · nonDerivative · entry 7 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,658 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.50 to $35.15, inclusive. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 400 | $33.75 | $13,500.00 |
DisclosureSEC source: 0001415889-21-001382 · form4-03092021_010305.xml · nonDerivative · entry 6 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,158 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.46 to $34.41, inclusive. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 775 | $32.97 | $25,551.75 |
DisclosureSEC source: 0001415889-21-001382 · form4-03092021_010305.xml · nonDerivative · entry 5 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,558 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.37 to $33.36, inclusive. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 4,315 | $31.87 | $137,519.05 |
DisclosureSEC source: 0001415889-21-001382 · form4-03092021_010305.xml · nonDerivative · entry 4 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,333 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.36 to $32.35, inclusive. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 2,500 | $30.92 | $77,300.00 |
DisclosureSEC source: 0001415889-21-001382 · form4-03092021_010305.xml · nonDerivative · entry 3 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,648 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.35 to $31.29, inclusive. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 2,677 | $29.68 | $79,453.36 |
DisclosureSEC source: 0001415889-21-001382 · form4-03092021_010305.xml · nonDerivative · entry 2 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,148 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 to $30.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (7) of this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionCommon Stock | 11,267 | $4.59 | $51,715.53 |
DisclosureSEC source: 0001415889-21-001382 · form4-03092021_010305.xml · nonDerivative · entry 1 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionStock Option (right to buy) · Derivative | 11,267 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001415889-21-000623 · form4-02102021_040201.xml · derivative · entry 4 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,226 Underlying: Common Stock · 11,267 shares Expires 2028-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F4 · derivative.exercise_date: The option to purchase 123,760 shares of common stock was granted on April 2, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on April 2, 2019 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 3,767 | $34.08 | $128,379.36 |
DisclosureSEC source: 0001415889-21-000623 · form4-02102021_040201.xml · nonDerivative · entry 3 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,558 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.60, inclusive. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 7,500 | $33.01 | $247,575.00 |
DisclosureSEC source: 0001415889-21-000623 · form4-02102021_040201.xml · nonDerivative · entry 2 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,325 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.52 to $33.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionCommon Stock | 11,267 | $4.59 | $51,715.53 |
DisclosureSEC source: 0001415889-21-000623 · form4-02102021_040201.xml · nonDerivative · entry 1 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. Read SEC document |
| January 22, 2021 Filed Feb 5, 2021 22:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 73,500 | $0.00 Strike: $30.25 | $0.00 |
DisclosureSEC source: 0001415889-21-000546 · form4-02052021_020207.xml · derivative · entry 1 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 Underlying: Common Stock · 73,500 shares Expires 2031-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2021. The shares underlying the option vest over four years, with 25% of the shares vesting on January 22, 2022 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:07 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionStock Option (right to buy) · Derivative | 11,267 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001415889-21-000313 · form4-01132021_010152.xml · derivative · entry 5 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,493 Underlying: Common Stock · 11,267 shares Expires 2028-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F5 · derivative.exercise_date: The option to purchase 123,760 shares of common stock was granted on April 2, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on April 2, 2019 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:07 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 300 | $28.80 | $8,640.00 |
DisclosureSEC source: 0001415889-21-000313 · form4-01132021_010152.xml · nonDerivative · entry 4 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,558 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.69 to $28.88, inclusive. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:07 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 4,721 | $28.05 | $132,424.05 |
DisclosureSEC source: 0001415889-21-000313 · form4-01132021_010152.xml · nonDerivative · entry 3 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,858 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.64 to $28.59, inclusive. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:07 UTC | Generation Bio Co. GBIO · Entity 67174 | SaleCommon Stock | 6,246 | $27.17 | $169,703.82 |
DisclosureSEC source: 0001415889-21-000313 · form4-01132021_010152.xml · nonDerivative · entry 2 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,579 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.62 to $27.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:07 UTC | Generation Bio Co. GBIO · Entity 67174 | Exercise / conversionCommon Stock | 11,267 | $4.59 | $51,715.53 |
DisclosureSEC source: 0001415889-21-000313 · form4-01132021_010152.xml · nonDerivative · entry 1 Kerr Douglas · CIK 0001814189 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.